Via Pharmaceuticals Stock Performance
| VIAP Stock | USD 0.0005 0.00 0.00% |
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Via Pharmaceuticals are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Via Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Via Pharmaceuticals is not utilizing all of its potentials. The recent stock price agitation, may contribute to short-term losses for the retail investors. ...more
Last Split Factor 1:15 | Last Split Date 2007-06-06 |
1 | MIRA Pharmaceuticals Sells Shares at 66 percent Premium - TipRanks | 10/16/2025 |
2 | Pharmaceuticals Limited Maintain Shareholder Returns via Buybacks - 2025 Bull vs Bear Reliable Momentum Entry Alerts - Trung tm D bo KTTV quc gia | 10/23/2025 |
3 | Tarsus sets Nov. 4 webcast to share thirdquarter results at 130 p.m. PT - Stock Titan | 10/28/2025 |
4 | Will Ironwood Pharmaceuticals Inc. stock maintain dividend yield - July 2025 Recap Short-Term Trading Opportunity Alerts - fcp.pa.gov.br | 11/05/2025 |
5 | Ranking Petros Pharmaceuticals Inc. among high performing stocks via tools - Earnings Miss AI Forecast Swing Trade Picks - newser.com | 11/14/2025 |
6 | Ranking Salarius Pharmaceuticals Inc. among high performing stocks via tools - Market Risk Summary Fast Moving Market Watchlists - newser.com | 11/19/2025 |
7 | Adial Pharmaceuticals enters 2.86M inducement at 0.31 exercise price - Stock Titan | 11/26/2025 |
Via Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.05 in Via Pharmaceuticals on September 26, 2025 and sell it today you would earn a total of 0.00 from holding Via Pharmaceuticals or generate 0.0% return on investment over 90 days. Via Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Via, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Via Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Via Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Via Pharmaceuticals, and traders can use it to determine the average amount a Via Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| VIAP |
Based on monthly moving average Via Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Via Pharmaceuticals by adding Via Pharmaceuticals to a well-diversified portfolio.
Via Pharmaceuticals Fundamentals Growth
Via Stock prices reflect investors' perceptions of the future prospects and financial health of Via Pharmaceuticals, and Via Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Via Stock performance.
| Return On Asset | -2.42 | ||||
| Current Valuation | 226.14 K | ||||
| Shares Outstanding | 20.56 M | ||||
| Price To Earning | (0.01) X | ||||
| Price To Book | 1.89 X | ||||
| EBITDA | (5.84 M) | ||||
| Net Income | (9.6 M) | ||||
| Cash And Equivalents | 84 K | ||||
| Total Debt | 14 M | ||||
| Current Ratio | 0.02 X | ||||
| Book Value Per Share | (0.90) X | ||||
| Cash Flow From Operations | (6.11 M) | ||||
| Earnings Per Share | (0.01) X | ||||
| Market Capitalization | 10.28 K | ||||
| Total Asset | 499.97 K | ||||
| Retained Earnings | (91.21 M) | ||||
| Working Capital | (18.55 M) | ||||
| Current Asset | 444 K | ||||
| Current Liabilities | 18.99 M | ||||
About Via Pharmaceuticals Performance
Assessing Via Pharmaceuticals' fundamental ratios provides investors with valuable insights into Via Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Via Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (22.08) | (20.98) | |
| Return On Capital Employed | 0.29 | 0.31 | |
| Return On Assets | (22.08) | (20.98) | |
| Return On Equity | 0.47 | 0.49 |
Things to note about Via Pharmaceuticals performance evaluation
Checking the ongoing alerts about Via Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Via Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Via Pharmaceuticals generated a negative expected return over the last 90 days | |
| Via Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Via Pharmaceuticals currently holds 14 M in liabilities. Via Pharmaceuticals has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Via Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (9.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Via Pharmaceuticals currently holds about 84 K in cash with (6.11 M) of positive cash flow from operations. | |
| Via Pharmaceuticals has a frail financial position based on the latest SEC disclosures |
- Analyzing Via Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Via Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Via Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Via Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Via Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Via Pharmaceuticals' stock. These opinions can provide insight into Via Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Via Stock Analysis
When running Via Pharmaceuticals' price analysis, check to measure Via Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Via Pharmaceuticals is operating at the current time. Most of Via Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Via Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Via Pharmaceuticals' price. Additionally, you may evaluate how the addition of Via Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.